Sr Scientist, Drug Metabolism jobs in United States
cer-icon
Apply on Employer Site
company-logo

Gilead Sciences · 12 hours ago

Sr Scientist, Drug Metabolism

Gilead Sciences is dedicated to creating a healthier world by tackling significant diseases such as HIV and COVID-19. They are seeking a Senior Scientist in Drug Metabolism to provide expertise in pharmacokinetics and modeling for biologics, guiding project teams through the discovery and development stages.

BiopharmaBiotechnologyHealth CareManufacturingPharmaceutical
check
Comp. & Benefits
check
H1B Sponsor Likelynote

Responsibilities

Provide advanced PK and PK/PD modeling expertise on project teams across discovery and development stages, guiding the design and interpretation of nonclinical PK, toxicology, and pharmacology studies
Lead quantitative DMPK strategy for biologics programs, collaborating with interdisciplinary teams to integrate modeling approaches into decision-making; communicate modeling insights and align strategies with scientists, collaborators, and management
Design, implement, and validate complex PK/PD and mechanistic models to address translational questions, support dose selection, and predict first-in-human exposures
Develop and refine modeling workflows for nonclinical study design, including simulation-based approaches to optimize study parameters and interpret outcomes
Prepare study protocols and coordinate execution of nonclinical studies which may involve multiple functional areas and CROs
Work closely with project teams, line management and CROs to assure high quality and timely delivery of written PK reports and regulatory documents (IND, IMPD, IB, BLA) for regulatory submissions
Participate in business development and licensing evaluations

Qualification

PharmacokineticsPK/PD modelingBiologics DMPKMechanistic modelingSimulation-based approachesPhoenix/WinNonlinMATLAB/SimBiologyR programmingIntellectual curiosityTeam collaborationCommunication skillsLeadership

Required

Bachelor's Degree and 8 Years' Experience
Masters' Degree and 6 Years' Experience
PhD/ PharmD and 2 Years' Experience
MD

Preferred

Ph.D. with 3+ years of post-graduate industry experience in pharmacokinetics, drug metabolism, pharmaceutics, or a related life science field, with a primary focus on quantitative modeling for large molecule/biologics PK characterization across discovery and development
Strong foundation in pharmacokinetics and pharmacodynamics principles, with demonstrated ability to translate these concepts into mathematical models
Extensive experience in mechanistic PK/PD and multi-compartmental modeling, including proficiency with software platforms such as Phoenix/WinNonlin, MATLAB/SimBiology, R, or equivalent modeling tools
Proven ability to design, implement, and interpret complex modeling workflows, determine next steps based on quantitative insights, and effectively communicate results to project teams and senior management
Demonstrated intellectual curiosity and commitment to staying current with advances in biologics DMPK and modeling methodologies, supported by a track record of external visibility through publications, presentations, and/or professional organization involvement

Benefits

Discretionary annual bonus
Discretionary stock-based long-term incentives (eligibility may vary based on role)
Paid time off
Company-sponsored medical, dental, vision, and life insurance plans

Company

Gilead Sciences

company-logo
Gilead Sciences is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases.

H1B Sponsorship

Gilead Sciences has a track record of offering H1B sponsorships. Please note that this does not guarantee sponsorship for this specific role. Below presents additional info for your reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (221)
2024 (246)
2023 (226)
2022 (208)
2021 (235)
2020 (187)

Funding

Current Stage
Public Company
Total Funding
$4.41B
Key Investors
Abingworth
2024-11-13Post Ipo Debt· $3.5M
2024-02-29Post Ipo Equity· $210M
2023-09-07Post Ipo Debt· $2B

Leadership Team

leader-logo
Keeley Wettan
Senior Vice President, Legal
linkedin
leader-logo
Patrick Loerch
Senior Vice President, Clinical Data Science
linkedin
Company data provided by crunchbase